INTRABODIES TARGETING POST-TRANSLATIONAL MODIFICATIONS OF NATIVE PROTEINS AND METHOD FOR OBTAINING THEM

Abstract

The present invention refers to a method for determining the ability of an immunoglobulin to bind to a post-translationally modified target in an intracellular environment, which folds and it is post-translationally modified as a native protein intracellularly. The present invention also refers to antibodies obtained by the above method and uses thereof.

Claims

1-56. (canceled)

57. A method for obtaining a human naïe scFv Single Pot Library of INTracellular antibodies (SPLINT), with the VH and VL domains derived from antibodies, the method comprising the steps of: a) amplifying human germline VH, Vk and Vλ regions, from a cDNA sample; b) amplifying a linker blunt specific for VH, Vk or Vλ regions, with primers having the same 3′ region annealing on the linker and different protruding 5′, overlapping perfectly either with VH framework 4 or VL framework 1 to obtain a semi-blunt linker; c) carrying out an overlap amplification between the variable region amplicons and the semi-blunt linkers, obtaining a VH-linker and a linker-VL, i.e. VH and VL, protruding with the same linker sequence at 3′ and 5′ respectively; d) joining VH-linker and linker-VL by overlapping amplification; e) inserting restriction sites at the 5′ of the VH regions and at the 3′ of the Vk and Vγ regions to obtain scFv products; f) digesting the scFv products with the specific restriction enzymes and ligating them to a digested vector.

58. The method according to claim 57 wherein the VH and VL domains are derived from antibodies of the IgM isotype.

59. The method according to claim 57 wherein the linker consists of a sequence of from 15aa to 19aa, and wherein the linker is not subjected to intracellular cleavage by proteases.

60. The method according to claim 57 wherein the primers used in step a) for Vk are: SEQ ID NOs: 38 and/or 39 and/or 40 and/or 41 and/or 42 and/or 43 and/or 44 and/or 45 and/or 46 and/or 47 and/or 48.

61. The method according to claim 57 wherein the primers used in step a) for Vλ are: SEQ ID NOs: 49 and/or 50 and/or 51 and/or 52 and/or 53 and/or 54 and/or 55 and/or 56 and/or 57 and/or 58.

62. The method according to claim 57 wherein the primers used in step a) for VH are: SEQ ID NOs: 24 and/or 25 and/or 26 and/or 27 and/or 29 and/or 30 and/or 31 and/or 32 and/or 33.

63. The method according to claim 57 wherein the primers used in step b) are: SEQ ID NOs: 59 and/or 60 and/or 61 and/or 62 and/or 63 and/or 64 and/or 65 and/or 66 and/or 67 and/or 68 and/or 69 and/or 70 and/or 71 and/or 72 and/or 73 and/or 74 and/or 75 and/or 76 and/or 77.

64. The method according to claim 57 wherein the cDNA of step a) is obtained by retro-transcribing heavy and light chains of IgM antibodies from RNA to cDNA.

65. The human naïe scFv SPLINT library obtainable by the method of claim 57.

66. The method according to claim 57 wherein the human germline VH, Vk and Vλ regions are made from isolated human splenocytes or isolated human peripheral blood lymphocytes.

67. The method according to claim 57 wherein the human germline VH, Vk and Vλ regions are made from isolated peripheral blood lymphocytes, with primers able to anneal at the beginning of the external framework regions of the V gene, producing a blunt product (Variable region amplicon).

68. The method according to claim 59 wherein the linker has SEQ ID NO: 94.

69. The method according to claim 64 wherein the method further comprises a preliminary step of extracting total RNA from isolated human splenocytes or isolated human peripheral blood lymphocites (PBLs).

Description

[0219] The present invention will be described by means of non-limiting examples referring to the following figures:

[0220] FIG. 1: PISA Tethered Catalysis Baits

[0221] In tethered catalysis baits used in PISA technology, the target antigen is fused to the enzyme that naturally catalyzes its PTM (e.g. HAT, Histone Acetyl Tranferase) in vivo. This fusion generates a constitutive, stable, in cis post-translational modification on the target protein. The antigen/enzyme construct is moreover fused at the c-term of LexA DNA binding domain, and at the N-term of a tag such as hemagglutinin (HA), forming in this way the “screening bait”. To discriminate intrabodies binding the PTM specifically, a panel of mutated baits is used. In particular, a bait that is identical to the screening bait but for a point mutation in the acetylating enzyme is used. This mutation inactivates the enzyme, causing the target protein not to be acetylated anymore. An anti-acetyl intrabody (or anti-PTM intrabody) will thus bind the screening bait but not the mutated bait.

[0222] FIG. 2: Western Blot analysis to check expression and acetylation status in yeast. a) Screening Bait LexA-Integrase-p300wt-HA and LexA-Integrase-p300mut-HA were immunoprecipitated from yeast protein extract after expression of bait plasmids, and blotted for HA tag (hemagglutinin). Membrane was then stripped and re-blotted with an anti-Acetyllysine pan-reactive antibody (CellSignal) to confirm acetylation occurs using WT construct only; b) Anti-HA blot for deletion control construct; c) LexA-Integrase bait was detected with a specific anti-Integrase antibody (left), which is able to recognize the full-length chimeric constructs as well. If stripped and blotted for Acetilated Lysines, no acetylation is shown without the acetyl-transferase (HAT) C-term fusion.

[0223] FIG. 3: Auto-Activation Test for Integrase Baits. Most of baits present no auto-activation if plated on a His-free medium (-WH). 1.25 mM of 3-AT was needed to turn off non-specificHis3 expression in LexA-HATwt and LexA-Integrase baits. LacZ marker auto-activation was also checked.

[0224] FIG. 4: Western Blot and 3-AT test for H3 baits. a) As done for IN baits, H3 screening bait (left) and controls (right) are analyzed by WB to check expression and specific acetylation. b) 3-AT test reveals that minimum concentration needed for LexA-H3-Gcn5wt-HA (screening bait) is 5 mM. Other 3-AT concentration used for control baits are shown.

[0225] FIG. 5: VH-112A domain intrabody is specific for Acetylated Integrase and it is not able to interact with non-acetylated version of the protein. a) Comparison between ScFv-112A and VH-112A intrabodies. The ScFv version of the selected prey cross-reacts with LexA-p300mut-HA. By using its VH domain instead, undesired activity completely disappears. Notably, 112A in both versions is NOT able to interact with non-acetylated integrase (IN-stop bait is not acetylated, see above). -WL (non-selective) plates are equally populated by cells; b) Single yeast colonies were restreaked from -WL plates to -WHL plates to further confirm specific growth. Remarkable is the absence of growth in all baits but the main one. c) Clones grown on -WL (non-selective) were used for beta-gal filter assay. Very clearly, the same interaction pattern is confirmed also with the second selection marker.

[0226] FIG. 6: In Vivo Epitope Mapping comparison between ScFv-12A and VH-12A. Splitting VH from VL improves antibody specificity and does not change its ability to bind Integrase bait. Data suggest VH12A has a preferential binding for Acetylated Integrase if compered to its ScFv version.

[0227] FIG. 7: Secondary screening of LexA-H3-Gcn5wt-HA. -WHL+3AT plates have been divided in sectors. Each plate represents one different bait, while each sector indicates the prey partner. As showed, ScFv-58F is the only intrabody that is able to grow in presence of the screening bait only.

[0228] FIG. 8: Beta-galactosidase liquid assay: Same amount of cell from non-selective medium was lysed using zymolase and freeze/thaw cycles. After that, cleared extracts were assessed for Beta-Gal presence using X-gal. As evident, 58F well turns blue only when using the main bait. Y1 represents an anti-LexA intrabody (positive control), whilst ScFv2 is the negative control, on which Absorbance results are normalized.

[0229] FIG. 9: Beta gal filter assay. Classic filter assay made from -WL yeasts showing same results obtained with the semi-quantitative liquid assay. Blue color of the screening bait/scfv2 couple is due to sensible autoactivation level of the bait (5 mM). Liquid assay was in fact preferred to this, since it minimizes “blue background”.

[0230] FIG. 10: In vitro acetylation of His-Integrase, WB analysis. Upper blot uses anti-AcLys to confirm acetylation occurred only when WT enzyme was used. Reaction was functional both with full length p300 and p300 catalytic domain. Positive control is represented from purified histon cores. Same samples were targeted with anti-his antibody to show presence of purified integrase (lower image).

[0231] FIG. 11: Co-Immunoprecipitation of Ac-Integrase using VH-112A intrabody. (a) anti-His W.B. of anti-HA Immunoprecipitates. VH-112A can immunoprecipitate Acetyl-Integrase only. Additional 15 kDa and 50 kDa bands are mouse immunoglobulins targeted by anti-mouse-HRP secondary antibody. (b) anti-HA blot of anti-HA immunoprecipitates, to check presence of the intrabody. Same experiments were conducted also by incubating His-IN with purified HATmut with no difference in results.

[0232] FIG. 12: Co-IP using anti-Integrase VH12A-HA. Experimental protocol is the same used with VH-112A-HA, except that final anti-HA resin was not boiled directly, but 1 mg/mL of HA peptide was used to displace the immunoprecipitated complex. Eluted surnatant thus, did not contain anti-HA antibodies and was analysed both with anti-HA and anti-his WB. His-AcIN and His-IN cannot be precipitated by resin alone, as shown in previous experiment.

[0233] FIG. 13: ELISA using VH-12A-HA and VH-112A-HA. In vitro detection of acetylated integrase was possible using VH-112A-HA antibody. VH-112A-HA instead recognizes both Integrase forms, but with more specificity for the non-acetylated one.

[0234] FIG. 14: ELISA with His-ScFv-58F. ScFv58F was expressed in bacteria with a His6× C-term tag and purified with TALON cobalt-based resin in a TBS buffer. Purified intrabody was then used as primary antibody for ELISA assay with eight different acetylated or non-acetylated yeast Histone peptides (coating, listed in the figure) to assess in vitro binding and targeted epitope. 58F-His was detected with a mouse anti-His antibody and subsequently with an anti-mouse HRP antibody. ScFv58F seems to target specifically AcK9 H3 peptide, with less preference for AcK9/AcK14 peptide.

[0235] FIG. 15: (a) Dot blot array of modified histone peptides to test ScFv-58F specificity. An annotated array of 384 modified histone peptides was incubated with scFv 58F, showing that scFv58F specifically binds to the Acetyl K9 variant of Histone H3 without cross-reacting with differently modified H3 peptide, nor with other histones. Two experimental replicas are shown in the Figure. The spot in the lower right part of the filter is a positive control (c-myc). (b) MODified Histone annotated array—Specificity Analysis. Data analysis performed with ActiveMotif software for the Histone MODified Annotated Array. ScFv-58F is strongly specificity for the acetylated lysine #9 of Histone H3 over other common modifications.

[0236] FIG. 16: Biochemical characterization and validation of anti-acetylated H3 histone intrabody ScFv-58F. Co-IP between ScFv-58F-HA and purified His-H3/HisAcH3 proteins (both expressed in E. coli, histone acetylated in vitro) using anti-HA agarose, followed by anti-HIS Western Blot. Lanes 1-2: the intrabody binds acetyl histone H3 with a strong prevalence over non acetylated H3

[0237] FIG. 17: ScFv-58F Binding data and specificity analysis. (a) ELISA dilution binding curve using 10 uM of acetylated (K9) or non acetylated H3 peptides coated on solid phase and different concentrations of ScFv-58F-HA as probe. (b) ELISA dilution binding curve using native acetylated H3 protein and H3AcK9 peptide, both coated on solid phase. The curves show a concentration range where ScFv-58F binds more effectively to the native acetylated protein than to the acetylated peptide.

[0238] FIG. 18: Intracellular Immunoprecipitation of endogenous acetylated Histone H3 (a) Immunoprecipitation with anti-HA agarose of chromatin solutions (soluble extracts) from yeast cells intracellularly expressing either ScFv-112A-HA, ScFv-58F-HA or ScFv-2-VP16. Membrane blotted for AcK9H3 and HA. Only ScFv-58F-HA is able to pull-down AcH3, while another unrelated anti-acetyl intrabody, such as ScFv-112A-HA, does not. (b) Immunoprecipitation of chromatin solutions from yeast cells intracellularly expressing either ScFv-2-VP16 or ScFv-58F-HA, blotted for AcK9H3. First panel from left shows chromatin ladder from soluble yeast extracts used in the IP experiment. Panel in the middle shows how anti-HA Ab efficiently immunoprecipitates ScFv-58F-HA bound to AcH3 histone and to low molecular weight chromatin (LMW chromatin). Last panel on the right shows an IP of chromatin solutions from both yeast cell samples with a polyclonal anti-AcK9H3 antibody. IPs of low and high molecular weight chromatin and of AcH3 are strongly impaired in yeast cells expressing ScFv-58F-HA . HMW=High Molecular Weight; LMW=Low Molecular Weight; Rb=Rabbit; M=Mouse; H-chain=Heavy chain (IP antibody); L-chain=Light chain (IP antibody); AcH3=Acetyl-K9-H3 Histone. (c) Relative quantification by western blot of Acetylated Histone H3 in yeast expressing ScFv-58F, ScFv-112A or no intrabody (L40). Acetylated H3 band density from two biological replicates was normalized on Total H3. AcH3 was detected with Merck-Millipore #06-599, while total H3 was detected with Abcam #1791. Data are shown as mean+/−S.D. N=2. Student T test analysis demonstrates no significative difference between samples. (d) Immunofluorescence of HeLa cells nuclei using ScFv-58F-HA highlights euchromatin and shows that labelling by scFv-58F-HA does not merge with Lamin staining.

[0239] FIG. 19 Functional validation of anti-Integrase intrabodies. HIV infectivity assay. (a) Left panel HeLa cells infected with HIV virus, previously transfected with VH-112A, show a reduced viral integration, when the intrabody is localized in the cytoplasm. A significant difference in viral integration is observed in cells expressing the intrabody, compared to control cells (expressing respectively a non-related intrabody (p<0.05, VH-2), the anti-integrase VH-12X (p<0.05), the backbone vector (p<0.05)) or compared to non-transfected but infected cells (p<0.001, CTRL+). The VH-12X intrabody is instead able to reduce infectivity with respect to CTRL+ with p<0.01, but only with p=0.058 and with p=0.078 if compared to VH-2 cyto and backbone respectively (comparison not shown). (b) Co-immunoprecipitation of HA-tagged antibody domains and different FLAG-tagged versions of Integrase proteins in HeLa cells. As previously (Cereseto et al. EMBOJ 2005), Flag-INwt construct is acetylated in mammalian cells, whilst Integrase mutated at Lysines 264, 266, 273 is not. As expected, only VH-112A is able to immunoprecipitate the AcIN selectively.

[0240] FIG. 20: Functional validation of anti-acetylated H3 histone intrabody ScFv-58F. Selective interference with acetylated H3 histone by the ScFv-58F intrabody regulates gene expression in yeast cells. (a) Heatmap of the significant differentially expressed genes between scFv112A (anti-acIN) and scFv58F (anti-H3AcK9) samples. Gene expression levels were filtered out to retain those showing a significant over- or under-expression (pAdj<0.05). Data were filtered according to the following conditions: i) pAdj<0.05 in the 58F-112A comparison; ii) L40-112A pAdj>0.05; iii) L40-58F pAdj<0.05. The values were normalized to the L40 sample levels. Four biological replicates for each sample were used. The list was further reduced applying a fold change threshold of 1.5. The statistical analysis was performed with R limma package and Benjamini correction was applied to the pValue (pAdj). In the graph, the marked (*) entries represent genes with a known association to histone acetylation. The heatmap in this Figure shows the most downregulated genes at the top, and the most upregulated genes at the bottom. (b) Principal Component Analysis on the microarray gene expression data. Each sample is composed of four independent biological replicates. Dim1 and Dim2 represent the first two principal components, the proportion of variance (POV) held by these components is reported in brackets as percentage. (c) Gene Ontology enrichment analysis of the dataset shown as heatmap in FIG. 3a. Barplot of the pValue associated to the most relevant Gene Ontology terms. GO enrichment analysis was performed on the significant differentially expressed genes between the ScFv-58F and ScFv-112A samples. The analysis and the most important terms were selected for the plot via David Ontology. (d) Validation by Real-Time PCR of selected differentially expressed genes between ScFv58F and ScFv112A samples. Data are shown as Log2(FC)+/−SD. SD=standard deviation=sqrt(SDSample2+SDL402). FC=Fold Change=2-ΔΔCt normalized on Actin (ACT1) and L40 samples. Student T test (58F VS 112A, homoscedastic, two-tailed) was performed on ΔCt values. P values: PH089=9.235E-06, PH084=1.911E-03, CTR1=3.116E-03, TRM11=2.248E-03, URH1=3.318E-03. A gene that was not differently expressed between ScFv58F and ScFv-112A was also used as a negative control (APC1, not shown).

[0241] FIG. 21: PISA bait system for phosphorylated protein antigens. Full-length human Tau protein has been fused with modified version of human GSK3β (constitutively active mutant S9A) to produce a screenable version of Phospho-Tau (screening bait). To permit counter-screening for anti-phospho-Tau binders, a control bait is also used, which has the same sequence of the screening bait, except for a different mutation in the GSK3β enzyme (K85A), which completely impedes kinase activity (control bait).

[0242] FIG. 22: Scheme illustrating the steps used for the construction of SPLINT human antibody libraries

[0243] FIG. 23: Implementation of the expanded genetic code in the PISA Technology. A pair of tRNA/AA-tRNA synthetase matching set able to work in yeast, is integrated in the S. cerevisiae L40 screening strain by an amber codon (UAG codon) re-allocation. The new strain is adapted to perform PISA screenings to select intrabodies against PTMs genetically encoded in the target antigen through the use of intragenic amber stops. UAA=unnatural amino acid.

[0244] FIG. 24: PISA.sup.2 2.0 selection mechanism. The tRNA(CUA) is expressed by yeast and in the cytosol it mediates the incorporation of Acetyllysine, thanks to the corresponding aminoacyl-tRNA synthetase. After translation, the LexA-acetylated protein (which is equipped with a NLS) is transported to the nucleus, where selection can occur. (Adapted from Hancock et al, 2010)

[0245] FIG. 25: IACT selection method. Briefly, IACT system is based on Y-2HY system, in which a genetically modified yeast not able to grow in absence of histidine is cotransformed with an antibody cDNA library and the target antigen. In the first construct (“the prey”, vector1), the antibody gene is fused to VP16 activation domain , whilst in the second construct, namely “the bait” (vector2), LexA DBD is at the very N-term of the fusion protein. Only in case an antibody is able to recognize the antigen intracellularly, this binding will be responsible of the activation of two reporter genes: HIS3 and LacZ. Thus, yeast plated on SD-WHL medium will now be able to grow in absence of histidine, and will metabolize X-gal due to beta-galactosidase production. Double positive clones (His+/Lacz+) are further analyzed by extracting prey plasmid DNA and testing it again against the antigen ti validate positivity. Last steps include in vitro characterization of the isolated antibody and mapping of the bound epitope.

[0246] FIG. 26: Interaction specificity for anti-IN ScFvs. Here is summarized the epitope mapping with the IN bait panel at the end of the secondary screening.

EXAMPLES

[0247] Materials and Methods

[0248] Here inventors show results and methods from two selections, aimed at the selection of antibody domains against two PTMs: acetylated HIV-1 integrase (accession number AF029884.1) and acetylated Histone H3 (gene ID 852295). Inventors engineered the following acetylated baits: a) LexA-Integrase-p300wt-HA and b) LexA-HistoneH3-Gcn5wt-HA. [“HAT” (Histone Acetyl Transferase or “p300” (gene id 2033), and “HAT” or “Gcn5” (gene ID 853167) are used herein indifferently].

[0249] Baits Construction

[0250] DNA template for bait construction was PCR-amplified and adapted from different Gal4 tethered catalysis baits, that were already validated from previous authors for presence of acetylation by western blot and mass spectrometry. Constructs regarding the H3 bait were adapted from Guo et al. (2004), whilst Integrase baits were created from Allouch et al. (2011) baits. All construct listed below represent inventors' final baits, with LexA DBD at the N-term, and they were cloned in both pMICBD1 and pMICBD2 plasmids (Visintin et al., 2004). Cloning was performed by restriction site cut/ligation procedure.

[0251] Baits used in the IACT primary screening procedure are named “screening baits” or “main baits”, and represent the version of the construct in which the catalytic domain of the acetylating enzyme (p300 or gcn5) is fully functional (Wild Type, “WT”). In this bait, the antigen (Integrase or H3) is constitutively acetylated, so through IACT it is possible to find intrabodies against any epitope of the bait, including acetylated and non-acetylated ones.

[0252] Thus, to screen for acetylation-specific antibodies, a panel of mutated baits is used. For instance, a pool of selected intrabodies against LexA-Integrase-p300wt-HA must be successively screened against LexA-Integrase-p300mut-HA, LexA-Integrase, LexA-p300wt-HA, LexA-p300mut to check that no interaction with these baits occur. In fact, intrabodies that recognize specifically the acetylated version of the integrase (or H3) will be able to interact with the screening bait exclusively, since it is the only construct in which the antigen is acetylated (FIG. 1).

TABLE-US-00002 TABLE 2 Table 2- List of baits constructed for PISA screening. INTEGRASE BAITS H3 HISTONE BAITS pMICBD1-LexA-Integrase- pMICBD1-LexA-H3-Gcn5wt-HA p300wt-HA (screening bait) (screening bait) pMICBD1-LexA-Integrase- pMICBD1-LexA-H3-Gcn5mut-HA p300mut-HA pMICBD1-LexA-Integrase pMICBD1-LexA-H3 pMICBD1-LexA-p300wt-HA pMICBD1-LexA-Gcn5wt-HA pMICBD1-LexA-p300mut-HA pMICBD1-LexA-Gcn5mut-HA pMICBD2-LexA-Integrase- pMICBD2-LexA-H3-Gcn5wt-HA p300wt-HA (screening bait) (screening bait) pMICBD2-LexA-Integrase- pMICBD2-LexA-H3-Gcn5mut-HA p300mut-HA pMICBD2-LexA-Integrase pMICBD2-LexA-H3 pMICBD2-LexA-p300wt-HA pMICBD2-LexA-Gcn5wt-HA pMICBD2-LexA-p300mut-HA pMICBD2-LexA-Gcn5mut-HA
This table includes plasimds prepared for PISA screening. pMICBD1 plasmids have been used for the screening, while pMICBD2 plasmids, that contain a version of LexA mutated in nuclear localization signal, have been produced, but they are used only in case there is need for a more stringent cytoplasmic selection.

[0253] Sequences:

[0254] Construct cloned in pMICBD1 or pMICBD2 are identical except for a LexA mutation described in Visintin et al. JIM (2004). The “LexA” part of the sequence refers to WT LexA (pMICBD1 plasmids), which are the only plasmids used to produce data herein shown.

TABLE-US-00003 >LexA-Integrase-p300wt-HA (SEQ. ID NO: 12) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFLDGIDKAQEEHEKYHSNWRAMASDFN LPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLA GRWPVKTVHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVIESMNKELKKIIGQVRDQAEHLKTAVQMA VFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDPVWKGPAKLLWKGEGAVVIQDNSDIK VVPRRKAKIIRDYGKQMAGDDCVASRQDEDRRRTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCY GKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQ ICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVE VKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRT AVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQA TEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNKKTSKNKSSLSRGNK KKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRR AQWSTMCMLVELHTQSQDRFVYTCNECYPYDVPDYA- >LexA-Integrase-p300mut-HA (SEQ. ID NO: 13) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFLDGIDKAQEEHEKYHSNWRAMASDFN LPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLA GRWPVKTVHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVIESMNKELKKIIGQVRDQAEHLKTAVQMA VFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDPVWKGPAKLLWKGEGAVVIQDNSDIK VVPRRKAKIIRDYGKQMAGDDCVASRQDEDRRRTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCY GKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQ ICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVE VKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLYSVHFFRPKCLRT AVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQA TEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNKKTSKNKSSLSRGNK KKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRR AQWSTMCMLVELHTQSQDRFVYTCNECYPYDVPDYA- >LexA-p300wt-HA (SEQ. ID NO: 14) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFTSRVYKYCSKLSEVFEQEIDPVMQSLGYC CGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPE LFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGE VTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYIS YLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNK KTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLT LARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRFVYTCNECYPYDVPDYA- >LexA-p300mut-HA (SEQ. ID NO: 15) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFTSRVYKYCSKLSEVFEQEIDPVMQSLGYC CGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPE LFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGE VTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYIS YLYSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAV SERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKREENTSNESTDVTKGDSKNAKKKNNK KTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLT LARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRFVYTCNECYPYDVPDYA- >LexA-IN (SEQ. ID NO: 16) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFLDGIDKAQEEHEKYHSNWRAMASDFN LPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLA GRWPVKTVHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVIESMNKELKKIIGQVRDQAEHLKTAVQMA VFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDPVWKGPAKLLWKGEGAVVIQDNSDIK VVPRRKAKIIRDYGKQMAGDDCVASRQDED- >LexA-HistoneH3-Gcn5wt-HA (SEQ. ID NO: 17) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFPGIRRPAANYLFDDEDTPPNPKKEIEFQL TTMFMARTKQTARKSTGGKAPRKQLASKAARKSAPSTGGVKKPHRYKPGTVALREIRRFQKSTEPGSPILGYWKGRR DHPPKSDLIEGRGDPEVKRVKLENNVEEIQPEQAETNKQEGTDKENKGKFEKETERIGGSEVVTDVEKGIVKFEFDGV EYTFKERPSVVEENEGKIEFRVVNNDNTKENMMVLTGLKNIFQKQLPKMPKEYIARLVYDRSHLSMAVIRKPLTVVG GITYRPFDKREFAEIVFCAISSTEQVRGYGAHLMNHLKDYVRNTSNIKYFLTYADNYAIGYFKKQGFTKEITLDKSIWM GYIKDYEGGTLMQCNMAIPGGGRIFYPYDVPDYAGYPYDVPDYAGSYPYDVPDYA- >LexA-HistoneH3-Gcn5mut-HA (SEQ. ID NO: 18) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFPGIRRPAANYLFDDEDTPPNPKKEIEFQL TTMFMARTKQTARKSTGGKAPRKQLASKAARKSAPSTGGVKKPHRYKPGTVALREIRRFQKSTEPGSPILGYWKGRR DHPPKSDLIEGRGDPEVKRVKLENNVEEIQPEQAETNKQEGTDKENKGKFEKETERIGGSEVVTDVEKGIVKFEFDGV EYTFKERPSVVEENEGKIEFRVVNNDNTKENMMVLTGLKNIFQKQLPKMPKEYIARLVYDRSHLSMAVIRKPLTVVG GITYRPFDKREFAEIVFCAISSTEQVRGYGAHLMNHLKDYVRNTSNIKYFLTYADNYAIGYAKKQGFTKEITLDKSIWM GYIKDYEGGTLMQCNMAIPGGGRIFYPYDVPDYAGYPYDVPDYAGSYPYDVPDYA- >LexA-Gcn5wt-HA (SEQ. ID NO: 19) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFPGIRRPGSPILGYWKGRRDHPPKSDLIE GRGDPEVKRVKLENNVEEIQPEQAETNKQEGTDKENKGKFEKETERIGGSEVVTDVEKGIVKFEFDGVEYTFKERPSV VEENEGKIEFRVVNNDNTKENMMVLTGLKNIFQKQLPKMPKEYIARLVYDRSHLSMAVIRKPLTVVGGITYRPFDKR EFAEIVFCAISSTEQVRGYGAHLMNHLKDYVRNTSNIKYFLTYADNYAIGYFKKQGFTKEITLDKSIWMGYIKDYEGGT LMQCNMAIPGGGRIFYPYDVPDYAGYPYDVPDYAGSYPYDVPDYA- >LexA-Gcn5mut-HA (SEQ. ID NO: 20) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFPGIRRPGSPILGYWKGRRDHPPKSDLIE GRGDPEVKRVKLENNVEEIQPEQAETNKQEGTDKENKGKFEKETERIGGSEVVTDVEKGIVKFEFDGVEYTFKERPSV VEENEGKIEFRVVNNDNTKENMMVLTGLKNIFQKQLPKMPKEYIARLVYDRSHLSMAVIRKPLTVVGGITYRPFDKR EFAEIVFCAISSTEQVRGYGAHLMNHLKDYVRNTSNIKYFLTYADNYAIGYAKKQGFTKEITLDKSIWMGYIKDYEGGT LMQCNMAIPGGGRIFYPYDVPDYAGYPYDVPDYAGSYPYDVPDYA- >LexA-H3Histone (SEQ. ID NO: 21) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKALARKGVIEIVSGASRGIRLLQEEEEGLPLV GRVAAGEPLLAQQHIEGHYQVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVARIDDEVT VKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVIRNGDWLEFPGIRRPAANYLFDDEDTPPNPKKEIEFQL TTMFMARTKQTARKSTGGKAPRKQLASKAARKSAPSTGGVKKPHRYKPGTVALREIRRFQKSTE-

[0255] Baits Validation

[0256] After plasmid DNA production, new baits were tested in yeast to check good intracellular expression, acetylation status and auto-activation phenomena. Auto-activation occurs when the bait alone, without any prey, is able to activate the transcriptional markers in L40 yeast strain, being able to grow in absence of histidine. This would affect the screening, since yeast has to grow only upon specific bait/prey co-expression. Indeed, His3 production of L40 strain genetically depends from LexA promoter, so that this enzyme is produced when a specific antibody interacts with a bait only. To avoid non-specific yeast growth, we used 3-AT chemical (3-amino-1,2,4-triazole), a specific inhibitor of His3 enzyme (responsible for Histidine production), to adjust his3 basal levels to zero. Required minimum 3-AT concentration is determined through a growth assay. All tests are made on stabilized yeast bait lines. (FIGS. 2, 3, 4)

[0257] P.I.S.A. Screenings

[0258] Screening is based on adaptation of IACT. In the method of the invention, LexA baits are totally different from classic IACT baits, since they are Post-translationally modified in cis by genetic fusion of an enzyme. As for the primary screening protocol, no substantial modifications have been made with respect to original paper (Visintin et al., 1999). (FIG. 16) During secondary screening, positive clones from primary screening are tested again with the main bait, and also with control constructs to map the targeted epitope intracellularly, in addition to LexA-Lamin (unrelated, LexA-fusion bait) and/or LexA-HA bait.

[0259] For both baits, a mouse naïe ScFv library (a SPLINT library) has been screened [Visintin et al.—“Intracellular antibodies for proteomics”—JIM (2004)] finding in each case a specific intrabody that is able to recognize the acetylated version of the antigen but not the non-acetylated one (FIG. 25).

[0260] LexA-Integrase-p300wt-HA Screening

[0261] This screening produced 2.25 million transformants (evaluated by counting serial cell dilutions on -SD−WL (minimum non-selective medium) (a minimum medium without tryptophan and leucine) plates). After O/N doubling in SD−WL medium, culture produced 4.5 doublings. Selected clones on SD-WHL [“minimum selective medium” (without tryptophan, leucine and histidine)] plates (screening plates, lacking histidine) were 500. Between day 4 to 6 after plating, biggest colonies were restreaked on fresh SD-WHL plates and a Beta-Galactosidase filter assay was performed to confirm double positives. Number of yeasts positives to both markers was 219. From these clones, a DNA fingerprint was performed, then prey plasmids were extracted, transformed in bacteria, mini-prepped as single clones, fingerprinted again to check for different preys, and co-transformed into control/main baits for secondary screening.

[0262] After secondary screening, we selected 3 true/different positives. Their interactions are summarized in FIG. 26.

[0263] 112A ScfV seemed to be a good candidate for Acetyl-Integrase specific binding, but a slight cross-reaction against the p300 bait was observed. Inventors thought that this effect could be moderated by splitting the ScFv into two separate Variable Domains (VH and VL), since antibody binding activity is often possessed and retained by one of the two variable regions.

[0264] Prey plasmids were then sequenced and analyzed though Abysis.org database, which permits easy recognition of domain antibodies ORFs. VH and VL have been thus subcloned in pLinker220 plasmid and used for a new secondary screening.

[0265] Astonishingly, use of VH domain of 112A intrabody resulted in highly specific in vivo interaction for the acetylated version of the bait (FIG. 5). No activity was observed using VL domain.

[0266] VH12A was also characterized and proven to be a general integrase binder, with preferential binding for Acetyl-Integrase. (Table 3)

TABLE-US-00004 TABLE 3 Interaction specificity of anti-IN VH domains compared to anti-IN ScFvs. IN- IN- LAMIN IN-stop HATwt- HATmut- HATwt- HATmut- (unrelated (non- HA HA HA HA bait) acetylated) ScFV + + − + − + 12A VH + − − − − + 12A ScFv + − − + − − 112A VH + − − − − − 112A
Table shows that VH domains of original selected ScFvs intrabodies not only retain binding activity, but also eliminate undesired cross-reaction effects.

[0267] LexA-H3-Gcn5wt-HA Screening

[0268] Transformants=8.8*10{circumflex over ( )}7; cell doublings after O/N in SD−WL=5; Selected clones on SD−WHL+10 mM 3AT plates=700. True positive clones (different sequences binding the screening bait)=3; True positive intrabodies that bind Acetyl-HistoneH3=1 (Table 4, FIG. 7).

TABLE-US-00005 TABLE 4 Epitope mapping for ScFv-58F. Table summarizes interaction of ScFv-58 intrabody against a panel of H3/H3 depleted baits, showing that LexA-H3-Gcn5wt-HA bait is the only bound bait. 2A 58F 249B y1 scfv2 LexA-H3- + + + + − Gcn5wt-HA LexA-H3- + − + + − Gcn5mut-HA LexA-Gcn5wt- +/−? − + + − HA LexA-Gcn5mut- +/−? − + + − HA LexA-Synuclein − − − + −

TABLE-US-00006 Sequence of described intrabodies >VH-12A (SEQ ID NO: 1)     10     20     30     40     50     60 QVQLQQSGAE LVKPGASVKL SCTASGFNIK DTYMHWVKQR PEQGLEWIGR IDPANGNTKY     70     80     90    100    110 DPKFQGKATI TADTSSNTAY LQLSSLTSED TAVYYCASLL WWGQGTLVTV SAASVSS Nucleotide sequence of VH-12A (VH-12X) (SEQ ID NO: 97) CAGGTTCAGCTTCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGG CCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATG CACTGGGTGAAGCAGAGGCCTGAA CAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTAATACTAAATATGA CCCGAAGTTCCAGGGCAAGGCCAC TATAACAGCAGACACATCCTCCAACACAGCCTACCTGCAGCTCAGCAGCCTGACAT CTGAGGACACTGCCGTCTATTACT GTGCTAGTCTACTATGGTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCTAGC GTTTCGAGC >VH-112A (SEQ ID NO: 2)     10     20     30     40     50     60 QVHVKQSGAE LVRPGASVKI SCKAFGYTFT NHHINWVKQR PGQGLEWIGY INPSTGYTEY     70     80     90    100    110    120 NQKFKDKATL TADKSSSTAY MQLSSLTSED SAVYYCASYY GSSYAMDYWG QGTSVTVSS Nucleotide sequence of VH-112A: (SEQ ID NO: 98) CAGGTCCACGTGAAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGCCT CAGTGAAGATTTCCTGCAAGGCTTTTGGCTACACCTTCACAAACCATCATATAAAC TGGGTGAAGCAGAGGCCTGGACAG GGTCTGGAATGGATTGGATACATTAATCCTAGCACTGGTTATACTGAGTACAATCAG AAGTTCAAGGACAAGGCCACATT GACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTGAGCAGCCTGACATCT GAGGACTCTGCAGTCTATTACTGTG CAAGTTACTACGGTAGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTC ACCGTCTCCTCAGCTAGCGTTTCG AGC >ScFv-58F (SEQ ID NO: 3)     10     20     30     40     50     60 DILMTQSPAI MSASPGEKVT MTCRASSSVS SSYLHWYQQK SGASPKLWIY STSNLASGVP     70     80     90    100    110    120 ARFSGSGSGT SYSLTISSVE AEDAATYYCQ QYSGYPWTSG GGTKLEIKRS GGSTSGSGKP     130    140    150    160    170    180 GSGEGSSSTE VKVEESGGGL VQPGGSMKLS CVASGFTFSN YWMNWVRQSP EKGLEWVAEI     190    200    210    220    230    240 RLKSNNYATH YAESVKGRFT ISRDDSESSV YLQMNNLRAE DTGIYYCTRR NGPSSRAMDY     250 WGQGTTVTVS S ScFv-58F heavy chain: (SEQ ID NO: 92) EVKVEESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAE IRLKSNNYATHYAESVKGRFTISRDDSESSVYLQMNNLRAEDTGIYYCTRRNGPSSRA MDYWGQGTTVTVSS ScFv-58F light chain: (SEQ ID NO: 93) DILMTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASG VPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPWTSGGGTKLEIKRSG Nucleotide sequence of ScFv-58F: (SEQ ID NO: 99) GATATTTTGATGACTCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAAAAGGT CACCATGACCTGCAGGGCCAGCTCA AGTGTAAGTTCCAGTTACTTGCACTGGTACCAGCAGAAGTCAGGTGCCTCCCCCA AACTCTGGATTTATAGCACATCCAAC TTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTC TCTCACAATCAGCAGTGTGGAGGC TGAAGATGCTGCCACTTATTACTGCCAGCAGTACAGTGGTTACCCGTGGACGTCCG GTGGAGGCACCAAGCTGGAAATAA AACGTTCCGGAGGGTCGACCAGCGGTTCTGGGAAACCAGGTTCCGGTGAAGGCT CGAGCAGTACCGAAGTGAAAGTTGA GGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGATCCATGAAACTCTCCTGTGTC GCCTCTGGATTCACTTTCAGTAACTA CTGGATGAACTGGGTCCGCCAGTCTCCAGAGAAGGGGCTTGAGTGGGTTGCTGAA ATTAGATTGAAATCTAATAATTATGCA ACACATTATGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCGA AAGTAGTGTCTACCTGCAAATGAACA ACTTAAGAGCTGAAGACACTGGCATTTATTACTGTACCAGGAGGAATGGACCCTCC TCCCGGGCTATGGACTACTGGGGTCA AGGAACCACGGTCACCGTCTCCTCAGCTAGCGTTTCGAGC Sequences of the CDRs of the obtained antibodies, with the CDRs defined according to Abysis.org predictions and Chothia numbering, are: (SEQ ID NO: 80) ScFv-58F CDRH1: G F T F S N Y (SEQ ID NO: 81) ScFv-58F CDRH2: R L K S N N Y A (SEQ ID NO: 82)  ScFv-58F CDRH3: R N G P S S R A M D Y (SEQ ID NO: 83) ScFv-58F CDRL1: R A S S S V S S S Y L H  (SEQ ID NO: 84) ScFv-58F CDRL2: S T S N L A S (SEQ ID NO: 85) ScFv-58F CDRL3: Q Q Y S G Y P W T (SEQ ID NO: 86) VH-112ACDR1: G Y T F T N H  (SEQ ID NO: 87) VH-112A CDR2: N P S T G Y (SEQ ID NO: 88) VH-112A CDR3: Y Y G S S Y A M D Y  (SEQ ID NO: 89) VH-12A CDR1: G F N I K D T (SEQ ID NO: 90) VH-12A CDR2: D P A N G N  (SEQ ID NO: 91) VH-12A CDR3: L L W 

[0269] In Vitro Characterization of Selected Intrabodies

[0270] Anti-PTM intrabodies were then assayed in vitro to further confirm their binding and their specificity. In this phase, new constructs were created, both for antigens and antibodies.

[0271] Anti-Acetyl-Integrase Intrabody VH-112A & Anti-Integrase Intrabody VH-12A-Co-Immunoprecipitation Assay With Purified Ac-Integrase

[0272] Preparation of the Cell Extracts Expressing VH-112A and VH-12A Intrabodies.

[0273] After true positive clones have been confirmed and mapped for the bound epitope, they were subcloned in bacterial expression plasmid pGIO1 (described in Meli et al.). Cloning was performed by previous cut of pLinker220 2HY clones with BssHII and NheI enzymes. After gel purification (ca. 750bp for ScFv and 400bp for VH), inserts were ligated to pGIO1 backbone opened with same enzymes. Plasmid was then modified with insertion of NheI-HA-NheI tag at the C-term of the intrabody. Resulting clones were checked by sequencing. Plasmids were transformed in BL21(DE3) bacterial strain. A single colony was used for O/N growth at 37° C. in LB+Kanamycin in a shaker (240rpm) . The day after, culture was diluted to OD600=0.2 and grown at 37° C. to OD600=0.55−0.70. Cultures are then induced with 0.5 mM IPTG at 25° C. for 5 h. Cell [E. coli BL21 (DE3)] pellets were lysed in TBS (20 mM TRIS, 150 mM NaCl—pH 8.0 was adopted for VH-112A-HA and pH 7.5 was used for VH-12A-HA)+Roche protein inhibitor Complete Mini with EDTA 1 mM, PMSF 1 mM+lysozime 1 mg/mL for 20 min RT, on a wheel. Samples were then sonicated on ice for 3 times, 10 sec each, with 1 minute rest between sonications. At this point lysated are incubated with DNase for 15min RT and spun 2×15 min at 4° C. at 16,100 rcf. Surnatant is preferably used fresh for Co-IP experiments, or can be stored in small aliquots at −80° C.

[0274] Preparation of the Acetylated Integrase

[0275] Integrase has been subcloned in pASK-IBA37 plus plasmid, a bacterial expression vector with 6× His tag at the N-terminus. After BL21 transformation, His-Integrase protein is purified with TALON resin (Invitrogen) as described in Allouch et al. (2011). 15 ug of Acetylated Integrase is then obtained by using either p300 catalytic domain from ActiveMotif or p300full from BsPBioscience in the following 50 min reaction at RT: 15 ug of purified His-Integrase (or histones), 5 uL of p300 enzyme, 1× HAT buffer (BSPBioscience), 200 uM Ac-CoA. Final volume 500 uL. In control reaction, recombinant p300mut was used. Acetylation was then checked with WB (see FIG. 10).

[0276] Procedure

[0277] Co-Immunoprecipitation experiments were performed between either purified His-tagged Acetyl-integrase (acetylated with p300 in vitro) or His-Integrase and bacterial cell [E. coli BL21 (DE3)] extract expressing VH-112A-HA (with appropriate controls, see FIG. 11). 250 uL (ca. 1900 ug) of VH-112A-HA cell extract was incubated with 50 uL of Pierce Anti-HA Agarose resin for 1.5 h at 4° C. on a rotating wheel. Then, samples were centrifuged at 700 rcf and washed twice with 400 uL of HAT Buffer 1× (by BPSBioscience, TBS-based buffer). Successively, 4.8 ug of appropriate antigen (Acetylated, non-acetylated or control) was added to the tube and incubated on the wheel at 4° C. for additional 2 h in a final volume of HAT buffer of 400 uL. At this point, samples are washed twice with 500 uL HAT buffer and twice with TBS-T 0.1% tween-20 (4 times total). All centrifugations were performed at 700 rcf, 2 min, 4° C. Resins were then boiled for 5min in 2×Laemmli buffer. Before loading samples on Acrylamide gel, samples were spun at 14,000 rcf for 2 min to pellet resin. SDS-PAGE was followed by W. B. using anti-His mouse monoclonal “Penta” antibody (Qiagen) to see co-precipitation and anti-HA rat monoclonal antibody (Roche, clone 3F10) to confirm intrabody presence.

[0278] In Vitro Detection of Integrase Through VH-HA Intrabodies

[0279] Purified His-Ac-Integrase or His-Integrase were used to coat wells from a 96-w plate at the concentration of 10 ng/uL, O/N 4° C., in carbonate buffer pH 9.6. After coating, lh blocking at 37° C. occurred (BSA 10 mg/mL) in PBST 0.05%. fresh cell extract containing VH-HA intrabodies was used to “capture” the HA-tagged prey. Cell extract was diluted in PBST/BSA 3% 2 h at 37C. Detection of retained intrabody domain was performed with anti-HA-HRP antibody (Roche), after 1 h incubation at 37° C. IN PBST/BSA 3%, with TMB. On the same plate the secondary HRP antibody alone was not able to recognize coated antigens. Wavelength read was 450 nm. In vitro, VH 12A seems to recognize sensibly better non-acetylated integrase. Washes between steps were 4× in PBST. (FIG. 13)

[0280] Anti Acetyl Histone H3

[0281] In Vitro Detection of H3 Acetylated Peptides with Cobalt Resin-Purified His-ScFv58F

[0282] 58F scfv was subcloned in pGIO1 (C-term V5 and His tag) and expressed in BL21cells [BL21(DE3)]. Proteins from cell pellet were extracted as described before for VH intrabodies using binding buffer (Tris 50 mM, NaCl 150 mM, Complete Mini Roche EDTA-free, PMSF 1 mM) pH8.5. Cell extract was incubated with TALON resin for 2 h at 4° C. on rotating wheel. Resin was previously equilibrated with the same buffer (2 500 uL washes). Follow 2 washes of ten minutes on wheel at 4° C. with binding buffer+5 mM Imidazole. Elution is performed with 200 mM Imidazole in binding buffer. Purified intrabody concentration was evaluated with Bradford assay and colorimetric comparison of run bands after SDS-PAGE/Coomassie staining.

[0283] E.L.I.S.A. was then performed in 96-well plate. Several acetylated and non-acetylated H3 yeast peptides have been used to coat plate (10 uM). Sequences were chosen from the yeast bait we have used for selections representing aa 1-21 or 10-29, and AcLys are the literature-illustrated PTM catalysed by Gcn5 on H3 N-term. Coating was verified with commercial anti-H3 and anti-AcH3 antibodies. List of the antigens:

TABLE-US-00007 (SEQ ID NO: 4) H3#1: ARTKQTARKSTGGKAPRKQLA (SEQ ID NO: 5) H3#2: ARTKQTAR(AcK)STGG(AcK)APRKQLA (SEQ ID NO: 6) H3#3: ARTKQTAR(AcK)STGGKAPRKQLA (SEQ ID NO: 7) H3#4: ARTKQTARKSTGG(AcK)APRKQLA (SEQ ID NO: 8) H3#5: ARTKQTARKSTGGKAPR(AcK)QLA (SEQ ID NO: 9) H3#6: STGGKAPRKQLASKAARKSA (SEQ ID NO: 10) H3#7: STGGKAPRKQLAS(AcK)AARKSA (SEQ ID NO: 11) H3#8: STGGKAPRKQLASKAAR(AcK)SA

[0284] After O/N coating at 4° C. in carbonate buffer, listed antigens were blocked in BSA 10 mg/mL for 1 h 37° C. Then, they were incubated with 58F-His (about 10 ng/uL) in TBST/BSA 3% for 2.5 h at 37° C.; follows 1 h incubation with anti-His Penta (mouse) and 1 h incubation with anti-mouse-HRP antibody. All dilution buffers were TBST 0.05% pH8.5. Antibody dilutions were made in TBST/BSA 3% buffer pH 8.5. Washes between steps 3×, final 5× in TBST pH 8.5. Anti-His Penta and anti-Mouse-HRP are not able to recognize coated antigens. Anti-Mouse-HRP antibody is not able to detect 58F-His.

[0285] The only form the intrabody could recognize specifically was peptide #3, that has AcK9 only. Acetylation of lysine 9 is an important modification for histone code, related to gene expression. Interestingly, very slight cross reaction is observed with AcK9/AcK14 form. (FIG. 14)

[0286] MODified Histone Peptide Array (Dot Blot)

[0287] To evaluate cross-reactivity of ScFv-58F against other PTM forms of histone H3 and against other histones, a dot blot array with more than 300 differently modifies histone peptides was probed with ScFv-58F-HA (FIG. 15). Results show that ScFv-58F is specific for acetylated lysine 9 of histone H3 and does not cross-react with any other acetylated, phosphorylated or methylated residue of histone H3, nor with any other histone protein. The HA-tagged antibody domain was purified by FPLC using an ionic exchange column. MODified Histone assay (Active Motif cat. No. 13001) was performed with FPLC-purified ScFv-58F-HA using standard western blot technique according to manufacturer's instructions. Briefly, ScFv-58F-HA was incubated o/n at 2 uM concentration in TBS, then detected with anti-HA antibody (Roche, 1:1000) and anti-Rat-HRP antibody (SCBT, 1:1000). Washes were made with TBS-T 0.05%.

[0288] ScFv-58F Specifically Binds and Immunoprecipitates Recombinant Native Acetylated Histone H3 In Vitro

[0289] ScFv-58F-HA was used to immunoprecipitate recombinant version of Histone H3 that was acetylated in vitro by Gcn5 enzyme (Active Motif cat.no 31204). FIG. 16 shows how 58F intrabody strongly immunoprecipitates the acetylated version of the native protein and has only a neglectable interaction with the unmodified histone, which is comparable to background observed with an anti-H3Ac commercial antibody (right-bottom panel) in western blots. Also, by controlling the concentration of ScFv-58F under 2 uM, as shown in next paragraph, it is possible to obtain a net recognition of acetylated histone H3 over the non-acetylated form. Co-immunoprecipitation assay was performed as follows: ScFv-58F-HA was expressed in bacteria using appropriate pGIO1 plasmid by induction of OD600=0.6 LB+Kanamycin E. coli BL21(DE3) culture with 0.5mM IPTG, for 4.5 h at 25° C., 225 rpm. Bacterial pellet is then lysed in lysis buffer (Tris 20 mM pH 8.0, NaCl 150 mM, EDTA 1 mM, lysozyme 1 mg/mL, PMSF 1 mM, complete Mini EDTA-free 1×). 250 μL ScFv-HA cell extract were added to 40 μL of anti-HA agarose (Thermo Scientific), and incubated on a rotating platform for 1.5 h at 4° C. This will purify the intrabody. Resin is washed once with ice-cold lysis buffer minus lysozyme and 2 times with 400 μL of ice-cold HAT buffer 1× (BPS bioscience). Antigen is then added to the resin (ca. 15 μg for Integrase and 2 μg for Histone H3) and 250 μL of HAT buffer 1× are also added. Control samples are also prepared to verify specific binding of antigen to the intrabody. Samples are incubated with rotation for 2 h at 4° C. Immunoprecipitates are washed twice with 500 μL of HAT buffer 1× and twice with 500 μL with TBS-T 0.1%. Resins are boiled in loading buffer for SDS-PAGE/western blot analysis.

[0290] ScFv-58F Binding Curves to Evaluate Affinity to Native Acetylated H3 Histone and Acetylated H3 Peptides

[0291] ScFv-58F-HA was employed in ELISA assay to quantitatively evaluate binding affinity and binding preferentiality against recombinant native H3 and H3 peptides (either acetylated or unmodified). Firstly, a direct-ELISA binding curve showed that the antibody domain loses its weak cross-reaction against the unmodified peptide if the concentration is lower than 2 micromolar (FIG. 17a). Then, the same assay was conducted using the recombinant, in vitro-acetylated H3 and the acetylated K9 peptide, demonstrating that 58F preferentially binds the native form of the antigen (FIG. 17b). 96-well plate was coated overnight with appropriate antigen at the concentration of 10 uM. Antibody dilutions are indicated in the figure legend.

[0292] ScFv-58F Binds Acetylated H3 In Vivo, Detects Chromatin of Yeast and Mammalian Cells, and Reduces Availability of Acetylated H3 in Yeast Cells.

[0293] To evaluate binding of ScFv-58F to endogenous protein, stable yeast lines intracellularly expressing the anti-AcK9H3 intrabody (IE-ScFv-58F-HA) or an unrelated control intrabody (IE-ScFv-112A-HA and/or IE-2-VP16 (IE-2-VP16 is identified with the ScFv-2 anti-Tau intrabody isolated in Visintin et al—“The Intracellular Antibody Capture Technology (IACT): Towards a Consensus Sequence for Intracellular Antibodies”—Journal of Molecular Biology-2002) or no intrabody (L40) in the nucleus, were used to prepare chromatin solutions for a chromatin immunoprecipitation experiment. In keeping with previous results, ScFv-58F binds yeast acetylated H3 also in vivo, since it is able to immunoprecipitate it after cell lysis and chromatin sonication (FIG. 18a). Moreover, IE-ScFv-58F is able to reduce acetylated histone availability in chromatin. Indeed, recognition of AcK9H3, as well as of associated chromatin, by exogenously-added anti-AcK9H3 polyclonal antibody, is almost totally impaired in extracts from cells expressing the ScFv-58F intrabody, further indicating that IE-ScFv-58F binds AcH3 in vivo and subtracts it from the chromatin pool that can be subsequently immunoprecipitated (FIG. 18b). Furthermore, the minor availability of acetylated chromatin in ScFv-58F-expressing samples is not dependent on an intrinsic feature of the used yeast, as the level of acetylated histones is the same for all the samples (FIG. 18c). These results were particularly important to define the possibility to assess the role of intrabody functionality on cellular protein network. To assess reactivity with human cell chromatin, FPLC-purified ScFv-58F-HA was used to perform an immunofluorescence on HeLa cells (FIG. 18d). Notably, the anti-AcK9H3 antibody domain is able to give a net euchromatic staining of the nuclei, which does not overlap with perinuclear lamin staining. Immunofluorescence protocol: Fixation: HeLa cells were fixed in 2% PFA for 12′ RT. Antigen retrieval: 3N HCl for 45′ RT. 1× wash with 0.1M tetraborate buffer pH 8.5 for 10′ RT. 2× wash with PBS 10′ RT. Blocking: PBS+BSA 1%+Triton-x-100 0.3% for 1 h at RT. Antibody I: ScFv-58F-HA 450 ng/uL in PBS/BSA o/n 4° C.; Lamin A Antibody (C-20): sc-6214 1:200 o/n 4° C. 3× washes PBS/BSA 10′ each RT. Antibody II: anti-HA Roche 1:500 or donkey anti-goat Alexa Fluor 633, 1 h RT. 3× washes PBS/BSA 10′ each RT. Antibody III: anti-Rat Alexa Fluor 488, 1:500. 3× washes. 3× washes PBS/BSA 10′ each RT. Imaging by Leica confocal microscopes.

[0294] Chromatin immunoprecipitation was performed as follows: yeast carrying pLinker220-ScFv-58F-HA or control plasmids were grown for 2 overnights in SD-L (lacking leucine) medium, then from OD600=0.3 to 0.65 in YPD (50 mL culture). Cells were spun at 2,000×g and washed 3 times with 30 mL of TBS, then resuspended in 1 mL TBS, spun again and pellet was frozen to −80° C. Day after cells were lysed in TBS-EDTA (IP buffer) using acid-washed glass beads (Sigma, cat. No G8772) and protease inhibitors (Roche cOmplete mini)+PMSF 1×. Lysates were transferred in new tubes and sonicated with Bioruptor™ (Diagenode) for 15 min cycle, high frequency at 4° C. and chromatin checked on 1.5% agarose gel (smear peak around 1000 bp). IP was conducted with anti-HA agarose (Thermo Scientific) o/n at 4° C. or with primary antibody+proteinG. Day after saples are washed 4 times with IP buffer+tween 0.05% for protein samples and 2 times for DNA samples followed by LiCl buffer and TE 1×. DNA IP samples were eluted in NaHCO3 0.1M/SDS 1% RT for 30min. Proteinase K was added and DNA was extracted by Phenol/Chloroform/Isoamyl alcohol (25/24/1). Precipitation is done o/n at −20° C. with absolute ethanol, pellets were washed with 70% ethanol and resuspended in 1×TE. Quantification was done with Invitrogen Q bit. Protein samples were instead boiled with resins after washing.

[0295] Functional Assays

[0296] Reduction of Viral Infectivity Upon VH-112A and VH-12A Administration

[0297] Acetylation of HIV-1 Integrase is known to enhance viral integration and infectivity (Cereseto et al.—EMBO Journal 2005). Since VH-112A specifically targets acetyl-Integrase while VH-12X (herein also referred as VH-12A) is an acetylation-independent Integrase binder, we compared their efficacy in an HIV-1 infectivity assay, to investigate possible effects of a specific anti-AcIN interference. HeLa cells transfected with either anti-Integrase intrabody, were infected, 48 hours later, with an HIV virus carrying a GFP reporter gene. Controls included cells transfected with an unrelated VH domain or with the plasmid backbone. The acetylation-specific cytoplasmic VH-112A intrabody significantly inhibits infectivity with respect to a non-related intrabody (p<0.05, VH-2), to the backbone (p<0.05), to non-transfected cells (p<0.001, CTRL+) or, also with respect to VH-12X (p<0.05) (FIG. 19a). The greater effectiveness of VH-112A, with respect to VH-12X in reducing the infectivity, highlights the importance of specifically targeting acetylated Integrase. Indeed, although VH-12X also showed a reduced infectivity when compared to the same controls, this reduction is significant with a lower confidence interval (FIG. 19a). To further confirm that inhibition of integration is due to interaction provided by VH-112A-HA and VH-12X-HA with (acetylated) Integrase, we set a co-immunoprecipitation experiment in the same cellular system where the Infectivity Assay was performed. Stable HeLa cell lines expressing HA-tagged anti-Ac-Integrase, anti-Integrase and anti-Tau (VH2) intrabodies were created. Then, these lines were transfected with Flagged constructs bearing either a wild type version of the Integrase, which is acetylated in mammalian cells by P30086, or a mutated, non-acetylated version of the protein. Western Blot in FIG. 19b clearly shows how the interaction profile of both the intrabodies is in keeping with results obtained in vitro, and confirms a significant intracellular interaction between the viral enzyme and the two single domains.

[0298] Altogether, the data demonstrate that targeting single PTM with PISA intrabodies leads to a significant and biologically relevant functional effect.

[0299] Procedure: HeLa cells were maintained in DMEM (GIBCO) supplemented with 10% FCS. The day before the experiment cells were seeded at 2×10{circumflex over ( )}5 cells per well in six-well plates. The lipofection was carried out with Effectene (QIAGEN) according to manufacturer's instructions. Cells have been transfected with 400 ng of pScFvExHA-VH-112A-HA, VH-12X-HA or VH-2-HA plasmids. After 48 h, cells have been transduced with the pWPXLD vector containing a GFP reporter. 48 h post-transduction, cells have been analyzed by FACS to measure infection efficiency by GFP fluorescence intensity. Intrabody expression was checked by WB on Bradford-quantified cell lysates. Immunoprecipitation was conducted on fresh cell extract overnight, using anti-HA agarose from Pierce.

[0300] Functional Validation of ScFv-58F: A Transcriptomic Study

[0301] Histone acetylation on lysine 9 is known to strongly regulate chromatin and transcription (Jenuwein et al—Science 2001). Therefore, we investigated which were the functional consequences of the expression of an anti-AcK9H3 binder in vivo. Indeed, masking AcK9H3 binding site in cells might avoid many bromodomain-containing proteins, which regulate chromatin, to bind their target and hence promote or regulate gene expression. We therefore sought to determine, by microarray analysis, the effects of ScFv-58F expression on the cell transcriptome, compared to the unrelated ScFv-112A and to untransfected L40 yeast. ScFv-112A represents a very strict control as it binds an acetylated antigen. PCA analysis showed that biological replicates of each of the three samples clusterize in well separated groups (FIG. 20a). We set analysis filters to understand if there was a set of genes that is specifically regulated by ScFv-58F. First of all, a threshold of minimum 1.5 in fold change was set. Secondly, genes were selected by their statistical significance (Padj<0.05, where Padj is the P value adjusted for the Benjamini correction) between ScFv-58F and ScFv-112A. These genes are also non-significant (PAdj>=0.05) between ScFv-112A and non transfected L40 strain, which allows to discriminate the general effect of any antibody domain expressed intracellularly. A heatmap was then constructed with resulting hits to show comparisons of the interesting genes between ScFv-58F and ScFv-112A. Data were normalised on L40 samples. Approximately one hundred mRNAs were selectively regulated in a statistically significant way by ScFv-58F, with a greater number of downregulated genes (FIG. 20b). The higher number of downregulated genes demonstrate the effect of silencing by the anti-acetyl-H3 intrabody. Gene Ontology (GO) enrichment analysis of these mRNAs was performed with online software David Ontology, and showed that the most affected GO terms include ion transport, phosphorus metabolism, oxidative phosphorylation, mitochondrial membrane, and ribosomal processing (FIG. 20c). A subset of the most significant hits was validated by Real-Time qPCR performed on the original RNA extracted from each sample, replicating with high grade of statistical significance the results obtained in the microarray (FIG. 20d). According to what found in Gene Ontology terms, among our most significant hits illustrated in the heatmap of FIG. 20b, we found PH084 and PH089, which are genes involved in the phosphate transport and metabolism. PHO genes are known to be strongly regulated by histone acetylation levels in yeast (Wongwisansri wt al.—Eukaryotic cell 2005). Indeed, PHOS and related PH084 and PH089 transcripts increase both by low levels of intracellular phosphate and both by depletion of RPD3 histone deacetylase. An augmented acetylation level allows chromatin remodelers like Snf2 to expose these genes to increased transcription. Thus, conditions in which histone acetylation is lower should correlate with a decreased expression of these genes. In our case, ScFv-58F intrabody is binding to Histone AcK9H3, silencing the action of acetylated chromatin. Notably, other genes we identified like the most strongly silenced can be correlated to histone acetylation, as found by previous authors for CTR1 (Wan et al.—FEBS Letter 2011). Finally, many genes and Gene Ontology categories found as the most significant hits are strictly related with each other, such as Phosphate metabolism genes and NAD+, ATP metabolism and mitochondria, indicating a possible indirect effect caused by the modulation of PHO genes. Thus, the intracellular interference with AcK9H3 by ScFv-58F did have significant functional consequences on the transcriptome and the effect observed is mainly classified as a silencing effect. This is the first evidence of a biological functional effect at a global transcriptomic level mediated by single-PTM inhibition in a living cellular system, which can only be provided by the described method.

[0302] Microarray yeast samples were processed as follows: Yeast glycerol stocks are restreaked on fresh plates (YPD for L40 wild type and SD-Leu for 112A and 58F) and incubated at 30° C. for 3d. A single CFU is inoculated in 10mL liquid culture with appropriate medium and shaked at 240 rpm at 30° C. overnight. Next day 1 mL of culture is used to inoculate a larger culture of 50 mL (using L40 or SD-Leu accordingly) and shaked at 240 rpm O/N at 30° C. Next day cultures are diluted in 50mL to OD600=0.2 in YPD and incubated O/N at 30° C. with shaking 240 rpm. Next day yeast is centrifuged (5 min 3,000×g) and total RNA is extracted using Yeast RiboPure® kit by ThermoFisher, which allows purification of total RNA without overload of ribosomal RNA. RNA quality is initially evaluated on DEPC/MOPS/formamide 1% agarose gel and with nanodrop measurement. Moreover, RNA was also checked using the Agilent BioAnalyzer 2100 (Agilent RNA 6000 nano kit): samples with a RNA Integrity Number (RIN) index lower than 8.0 were discarded. All the experimental steps involving the labelling, hybridization and washing of the samples were done following the one-color Agilent protocol.

[0303] PISA Selections Against Phospho-Tau Bait

[0304] Tau protein stabilizes microtubules, and it is abundant in neurons of the central nervous system and are less common elsewhere, but are also expressed at very low levels in CNS astrocytes and oligodendrocytes. Pathologies and dementias of the nervous system such as Alzheimer's disease and Parkinson's disease (Lei et al—Int Journ Biochem Cell Biol 2010) are associated with tau proteins that have become defective and no longer stabilize microtubules properly.

[0305] Hyperphosphorylation of the tau protein by GSKβ and other kinases can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease, frontotemporal dementia, and other tauopathies (Alonso et al.—PNAS 2001). However, no current available chemical that inhibit Tau is able to distinguish between the differently phosphorylated versions of the protein. This task is exclusively achievable with PISA intrabodies and will help to study the biology of phospho-Tau and its clinical significance, besides being a potential new and powerful inhibitor for therapeutic usage.

[0306] PISA tethered catalysis bait panel encoding phosphorylated Tau protein has been created, and stable yeast bait lines have been established. (FIG. 21). Tau full-length protein coding sequence (NCBI accession number: KR711804) has been fused at the N-terminus of either GSK3β kinase (NCBI accession number: BC012760), which is a constitutively activated mutant version bearing the S9A mutation, or at N terminus of the GSK3β K85A mutant, which instead is not able to catalyse the phosphorylation of Tau. Protein target/kinase fusion is also fused with LexA DNA binding domain at the N-terminus and with HA tag at the very C-terminus, as illustrated in FIG. 21.

[0307] Bait was constructed using classic cloning techniques (PCR amplifications, overlap PCR and restriction enzyme cut/ligations). PISA selections were performed as described above for acetylated baits, and yielded about one hundred of positive intrabody clones (primary screening selection), prior to the secondary selection, which led to the finally selected anti phosphoTau intrabodies.

[0308] Construction of the First Human Single Domain VH and Scfv SPLINT Library

[0309] In addition to the scFv antibody domains, which have been described above, single domain antibodies (e.g. either Variable Heavy or Variable Light domain only of an Immunoglobulin) are a popular recombinant antibody format widely used in in vitro display technologies [e.g. camelid single domains, also called “nanobodies” (Helma et al—The Journal of Cell Biology 2015)].

[0310] Despite the fact that single antibody domains would be very useful as intrabodies, due to their small size, their derivation from a naive human library has never been reported, since it would be anticipated that human single domain antibodies (VH or VL) would not have an affinity sufficiently high for practical uses. For this reason, the possibility of exploiting the natural human IgM repertoire has never been explored for naive SPLINT libraries of VH domains, since it is expected that good binders would not be isolated successfully. Indeed, Human single domain antibodies have been sofar isolated by IACT selection only from synthetic libraries, (Tanaka et al—Journal of Molecular Biology 2003), made from a fixed scaffold with random variability on the third Complementarity Determining Region (CDR3). Two SPLINT human libraries, one in the ScFv format and one in the single VH domain format, were constructed and screened against PISA baits described in this document as well as against a number of other different antigens in IACT selections. Surprisingly, we obtained the unexpected result that true positive intrabodies could be de novo selected not only from the human SPLINT scFv library but also, unexpectedly and against the predictions, from the naive SPLINT library of human single VH domains. Thus, VH domains were successfully selected from naive SPLINT VH library against various antigens, including the extracellular fragment of Neuroligin 3 and Cytochrome C and against PTM proteins. Deep sequencing analysis of the libraries showed that the naive scFv and VH human SPLINT libraries have high quality and diversity (>10.sup.7 for the scFvs and >6×10.sup.6 for VHs respectively).

[0311] A scheme of the construction procedure is described in FIG. 22.

[0312] Construction of Human SPLINT ScFv Libraries

[0313] Antibody domain libraries have been generated from human lymphocytes extracted from peripheral blood (PBLs). PBLs were isolated from blood buffy coat of four voluntary donors with Ficoll-Paque. More than 10.sup.8 PBLs have been subjected to RNA extraction with trizol reagent, then antibody IgM (heavy and light chains) were retro-transcribed with specific oligos annealing in the constant region. After cDNA was obtained, VH and VL (both kappa and λ) regions were amplified by PCR with a specific set of primers extensively modified and optimised from Marks and Bradbury (Methods in Molecular Biology 2004). These oligos are able to anneal at the beginning of the external framework regions of the V genes, producing a “blunt” product, with virtually no possibilities of overlap. To amplified VHs were used 6 oligos for the 5′, and 4 oligos for the 3′. Every possible combination of these primers was used generating 24 different classes of VHs. To amplify Vks were used 6 oligos for the 5′, and 5 oligos for the 3′. Every possible combination of these primers was used generating 30 different classes of VKs. To amplify Vλs were used 7 oligos for the 5′, and 3 oligos for the 3′. Every possible combination of these primers was used, generating twenty-one different classes of Vλs.

[0314] At this point, VH regions were joined to Vk and Vλ, through a process called “pullthrough”. To this aim, a (G4S)3 linker of 45 bp was amplified from a pre-existing plasmid using a new set of primers, with the same 3′ region annealing on the linker, and different protruding 5′, overlapping perfectly either with VH framework4 or VL framework1. This amplification generates a “semi-blunt” product mix, that is able to overlap to VH or VL only. Third step consists in overlap PCR between the Variable region amplicons and the semi-blunt linkers, resulting in VH and VL protruding with the same linker sequence at 3′ and 5′ respectively.

[0315] The fourth step is made by joining VH-linker and linker-VL products in a final overlapping PCR. After a few cycles, primers for the 5′ of VHs bearing restriction site for NheI and primers for the 3′ of Vks or Vλs bearing restriction site for BssHII were added to the mix, generating the final 750bp scFv product. Finally the pullthrough products were digested with NheI/BssHII enzymes and ligated to the NheI/BssHII digested vector pLinker220.

[0316] Construction of Human SPLINT VH Library

[0317] The starting RNA was the same used for hscFV1 library. Amplification of VH subclasses was performed using in a single reaction a mix of the 6 primers for the 5′ (bearing BssHII restriction site) and of the 4 primers for the 3′ (bearing NheI restriction site) specific for VH. VH products were digested with BssHII/NheI enzymes and ligated to the BssHII/NheI digested vector pLinker220. Transformation efficiency was assessed as described before and resulted to be 6×10.sup.6.Transformed bacteria were inoculated in LB-SeaPrep Agarose (Lonza Rockland, Inc.) as described in Elsaesser 72. Plasmids were extracted with Qiagen Plasmid Giga Kit.

TABLE-US-00008 Primers used for cDNA amplification (SEQ ID NO: 22) HuCκFOR: 5′ AGACTCTCCCCTGTTGAAGCTCTT 3′  (SEQ ID NO: 23) HuCLFOR: 5′ TGAAGATTCTGTAGGGGCCACTGTCTT 3′  Primers used for library construction Primers for VH (SEQ ID NO: 24) BssHII-HuVH1aBACK: 5′ gCCgcgcgcatgccCAGGTGCAGCTGGTGCAGTCTGG 3′  (SEQ ID NO: 25) BssHII-HuVH2aBACK: 5′ gCCgcgcgcatgccCAGGTCAACTTAAGGGAGTCTGG 3′  (SEQ ID NO: 26) BssHII-HuVH3aBACK: 5′ gCCgcgcgcatgccGAGGTGCAGCTGGTGGAGTCTGG 3′  (SEQ ID NO: 27) BssHII-HuVH4aBACK: 5′ gCCgcgcgcatgccCAGGTGCAGCTGCAGGAGTCGGG 3′  (SEQ ID NO: 28) BssHII-HuVH5aBACK: 5′ gCCgcgcgcatgccGAGGTGCAGCTGTTGCAGTCTGC 3′  (SEQ ID NO: 29) BssHII-HuVH6aBACK: 5′ gCCgcgcgcatgccCAGGTACAGCTGCAGCAGTCAGG 3′  (SEQ ID NO: 30) HuJH1-2FOR: 5′ TGAGGAGACGGTGACCAGGGTGCC 3′  (SEQ ID NO: 31) HuJH3FOR: 5′ TGAAGAGACGGTGACCATTGTCCC 3′  (SEQ ID NO: 32) HuJH4-5FOR: 5′ TGAGGAGACGGTGACCAGGGTTCC 3′  (SEQ ID NO: 33) HuJH6FOR: 5′ TGAGGAGACGGTGACCGTGGTCCC 3′  Primers for hVH single domain library (SEQ ID NO: 34) NheI-HuJH 1-2 FOR: 5′ CGGCCGCGCTAGCTGAGGAGACGGTGACCAGGGTGCC 3′  (SEQ ID NO: 35) NheI-HuJH 3 FOR: 5′ CGGCCGCGCTAGCTGAAGAGACGGTGACCATTGTCCC 3′  (SEQ ID NO: 36) NheI- HuJH 4-5 FOR: 5′ CGGCCGCGCTAGCTGAGGAGACGGTGACCAGGGTTCC 3′  (SEQ ID NO: 37) NheI-HuJH 6 FOR: 5′CGGCCGCGCTAGCTGAGGAGACGGTGACCGTGGTCCC 3′  Primers for Vk (SEQ ID NO: 38) HuVκ1aBACK: 5′ GACATCCAGATGACCCAGTCTCC 3′  (SEQ ID NO: 39) HuVκ2aBACK: 5′ GATGTTGTGATGACTCAGTCTCC 3′  (SEQ ID NO: 40) HuVκ3aBACK: 5′ GAAATTGTGTTGACGCAGTCTCC 3′  (SEQ ID NO: 41) HuVx4aBACK: 5′ GACATCGTGATGACCCAGTCTCC 3′  (SEQ ID NO: 42) HuVκ5aBACK: 5′ GAAACGACACTCACGCAGTCTCC 3′  (SEQ ID NO: 43) HuVκ6aBACK: 5′ GAAATTGTGCTGACTCAGTCTCC 3′  (SEQ ID NO: 44) NheI-HuJκ1FOR: 5′ CGGCCGCgctagcACGTTTGATTTCCACCTTGGTCCC 3′  (SEQ ID NO: 45) NheI-HuJκ2FOR: 5′ CGGCCGCgctagcACGTTTGATCTCCAGCTTGGTCCC 3′  (SEQ ID NO: 46) NheI-HuJκ3FOR: 5′ CGGCCGCgctagcACGTTTGATATCCACTTTGGTCCC 3′  (SEQ ID NO: 47) NheI-HuJκ4FOR: 5′ CGGCCGCgctagcACGTTTGATCTCCACCTTGGTCCC 3′  (SEQ ID NO: 48) NheI-HuJκ5FOR: 5′ CGGCCGCgctagcACGTTTAATCTCCAGTCGTGTCCC 3′  Primers for Vλ (SEQ ID NO: 49) HuVλ1BACK: 5′ CAGTCTGTGTTGACGCAGCCGCC 3′  (SEQ ID NO: 50) HuVλ2BACK: 5′ CAGTCTGCCCTGACTCAGCCTGC 3′ (SEQ ID NO: 51) HuVλ3BACK: 5′ TCCTATGTGCTGACTCAGCCACC 3′  (SEQ ID NO: 52) HuVλ3bBACK: 5′ TCTTCTGAGCTGACTCAGGACCC 3′  (SEQ ID NO: 53) HuVλ4bBACK: 5′ CACGTTATACTGACTCAACCGCC 3′  (SEQ ID NO: 54) HuVλ5BACK: 5′ CAGGCTGTGCTCACTCAGCCGTC 3′  (SEQ ID NO: 55) HuVλ6BACK: 5′ AATTTTATGCTGACTCAGCCCCA 3′  (SEQ ID NO: 56) NheI-HuJλ1FOR: 5′ CGGCCGCgctagcACCTAGGACGGTGACCTTGGTCCC 3′  (SEQ ID NO: 57) NheI-HuJλ2-3FOR: 5′ CGGCCGCgctagcACCTAGGACGGTCAGCTTGGTCCC 3′  (SEQ ID NO: 58) NheI-HuJλ4-5FOR: 5′ CGGCCGCgctagcACCTAAAACGGTGAGCTGGGTCCC 3′  Primers for Linkers (SEQ ID NO: 59) PlusLinker(G4S)3: 5′ GGTGGAGGCGGTTCAGGCGGAG 3′  (SEQ ID NO: 60) MinusLinker(G4S)3: 5′ CGATCCGCCACCGCCAGAGCCAC 3′  (SEQ ID NO: 61) RHuJH1-2: 5′ GCACCCTGGTCACCGTCTCCTCAGGTGG 3′  (SEQ ID NO: 62) RHuJH3: 5′ GGACAATGGTCACCGTCTCTTCAGGTGG 3′  (SEQ ID NO: 63) RHuJH4-5: 5′ GAACCCTGGTCACCGTCTCCTCAGGTGG 3′  (SEQ ID NO: 64) RHuJH6mod: 5′ GGACCACGGTCACCGTCTCCTCAGGTGG 3′ (SEQ ID NO: 65) RHuVκ1aBACKFv: 5′ GGAGACTGGGTCATCTGGATGTCCGATCCGCC 3′  (SEQ ID NO: 66) RHuVκ2aBACKFv: 5′ GGAGACTGAGTCATCACAACATCCGATCCGCC 3′  (SEQ ID NO: 67) RHuVκ3aBACKFv: 5′ GGAGACTGCGTCAACACAATTTCCGATCCGCC 3′  (SEQ ID NO: 68) RHuVκ4aBACKFv: 5′ GGAGACTGGGTCATCACGATGTCCGATCCGCC 3′  (SEQ ID NO: 69) RHuVκ5aBACKFv: 5′ GGAGACTGCGTGAGTGTCGTTTCCGATCCGCC 3′  (SEQ ID NO: 70) RHuVκ6aBACKFv: 5′ GGAGACTGAGTCAGCACAATTTCCGATCCGCC 3′  (SEQ ID NO: 71) RHuVλBACK1Fv: 5′ GGCGGCTGCGTCAACACAGACTGCGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 72) RHuVλBACK2Fv: 5′ GCAGGCTGAGTCAGAGCAGACTGCGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 73) RHuVλBACK3aFv: 5′ GGTGGCTGAGTCAGCACATAGGACGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 74) RHuVλBACK3bFv: 5′ GGGTCCTGAGTCAGCTCAGAAGACGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 75) RHuVλBACK4Fv: 5′ GGCGGTTGAGTCAGTATAACGTGCGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 76) RHuVλBACK5Fv: 5′ GACGGCTGAGTCAGCACAGACTGCGATCCGCCACCGCCAGAG 3′  (SEQ ID NO: 77) RHuVλBACK6Fv: 5′ TGGGGCTGAGTCAGCATAAAATTCGATCCGCCACCGCCAGAG 3′ 

[0318] Applications

[0319] IntraChIP and Anti-Histones Intrabodies

[0320] Currently, first step towards functional validation and first application using 58F intrabody (anti-H3Ac) have been made. An HA tag has been added to c-term of pLinker-58F plasmid, the yeast expression vector used for selection. This will avail easy tracking and manipulation of the intrabody in yeast L40 cells and other strains.

[0321] One of the most important applications envisaged for an anti-Histone antibody is surely Chromatin Immunoprecipitation (ChIP). Normally, ChIP is performed by firstly crosslinking chromatin with paraformaldehyde. Then, cells are lysed, DNA is sonicated, and finally chromatin is immunoprecipitated with antibodies to Histones or a particular transcription factor. However, formaldehyde used before antibody probe could alter Histone Lysines creating an analysis bias; crosslinking is empirical, poorly understood mechanism (Gavrilov, 2014). Manipulating chromatin before immunoprecipitation, could thus lead to loss of information and/or biases in obtained information.

[0322] By using our 58F intrabody, we aim to investigate if a consistent improvement of IP can occur. The idea is that of expressing the anti-AcH3 intrabody as a first thing within yeast and then proceed with IP protocol. We called the application, for this reason, “IntraChIP”. Replication of a well-studied yeast IP case will help to compare gene reads from classic IP and our IntraChIP version. Comparison can be done between 58F used as intrabody, 58F purified and used as normal, “external” antibody, and a commercial antibody. Since H3K9 acetylation is associated with DNA transcription, any exclusive IntraChIP gene read can be validated checking for RNA levels associated to that gene.

[0323] Moreover, anti-AcH3 intrabodies can be seen as novel tools to study histone code and the “epigenetic fingerprint” of living cells. Perturbation induced by chemicals to alter chromatin are often obtained by targeting modifying enzymes, which easily leads to consequent perturbations of other downstream pathways. By targeting chromatin from inside, the real epigenetic state of a cell in a determined condition can be targeted and, eventually, manipulated directly. First evidences of intrabodies used to localize histones in living cell has already been shown (Sato et al., 2013), but by previously selected antibodies, which functions only in particular cases. For this reason, stunning scientific interest is behind having a general intrabody selection platform against PTM histones and PTM in general.

[0324] Target Validation and Therapeutic Applications

[0325] PTModifications play an important role in pathological processes too. A peculiar example is that of Integrase of HIV-1 (which may be represented by the sequence of NCBI Accession number AF029884.1 or fragments thereof). Indeed, it is known that acetylation by p300 (which may be represented by the sequence of gene id 2033 or fragments thereof) enzyme is crucial for integration of viral genome in the host genome (Cereseto et al., 2005). Moreover, epigenetic of tumors has shown that important chromatin remodeling can occur instead of simple gene mutation, and tools for chromatin targeting and remodeling are needed (Siddiqi et al, 2010; Beltran et al., 2008).

[0326] In both cases, therefore, these and other PISA antibodies could play an important role in target validation studies and therapeutic applications. In general, the ability to perform PTM-selective and PTM-specific protein interference studies in living cells with the isolated anti PTM intrabodies is novel and would be extremely useful as a generic tool for target validation and for therapeutic purposes. Also, the isolated antibodies are very useful as “macrodrugs”, i.e. as protein templates with a specificity for a given PTM, that can be used as a lead to isolate chemical small molecules with similar PTM specificity.

[0327] Intracellular protein networks are complex webs of protein-protein interactions, in which the proteins are nodes of the network and the protein-protein interactions are the edges. PTMs establish a conditional link (or edge) between two proteins and thus represent molecular switches that make a protein-protein interaction conditional on a signal. No current method for functional interference with proteins in a cell allow for the Edge-specific disruption of intracellular protein networks. Indeed, nucleic-acid based methods, even if very powerful (gene KO, RNA interference, CRISPR Cas9), determine the ablation, silencing or interference of nodes (the global pool of a given protein) regardless of their post-translational modifications or status. The method of this invention allows to achieve, in a generic and streamlined way, exactly this: PTM-selective and PTM-specific protein interference studies in living cells with the isolated anti PTM intrabodies.

[0328] Introduction of PISA Selected Antibodies in Target Cells

[0329] In target validation and in therapeutic applications, the PISA selected antibodies can be used i) as genes, expressed in the target cells by well known gene transfer and gene therapy approaches (Marshall—Science 2000), or ii) as proteins, introduced into cells by one of several known cell penetrating peptides (CDP) (Cerrato et al—Expert Opin Drug Deliv 2016).

[0330] A First Generation of Chemicals That Target PTM Epitopes Directly

[0331] As discussed above, current generation chemicals employed in pathology treatment and targeting post-translational mechanisms, are directed against modifying enzymes, rather than against specific modified downstream substrate targets. Among these enzymes there are also activated kinases, which are often themselves phosphorylated in their active state. However, selection of small chemicals relies on inhibition of enzyme activity, therefore it is way more likely to isolate molecules that bind the catalytic pocket of the enzyme, rather than the post-translational modification itself. In cellular protein networks, instead, the PTM itself represents an “interaction edge”, and is the binding site of other molecular partners. Being able to distinguish between “targeting a PTM-protein” (regardless of the epitope bound on it) and “targeting the protein PTM” (directly, as PISA allows) would therefore provide the deepest level of control on regulation of protein-protein interactions, permitting at the same time to have a new weapon in the field of pharmaceuticals. In addition to being used as intrabodies, PISA antibodies can be used as scaffolds to derive small chemical mimics (New Chemical Entities, NCE). Thus, PISA technology will help mimicking (and thus synthesizing) new anti-PTM chemicals by furnishing structural and chemical information about the binding site of the intrabody, which can be co-crystallized with the PTM-protein. Indeed, PISA selection and counter-selection scheme is designed to isolate antibody domains binding the modified aminoacid(s) of the protein antigen.

[0332] PISA 2.0: Expanded Genetic Code Technology Applied to PISA Screenings

[0333] The presented method allows an obvious extension and facilitation, surpassing tethered catalysis to incorporate the PTM into the antigen bait, and substituting tethered catalysis with the expanded genetic code strategies. In this case, the PTM is genetically encoded directly into the target gene. In this advanced method that inventors call “PISA 2.0” (FIGS. 23 and 24), L40 yeast strain (or another 2-hybrid system strain) is genetically modified to stably express two constructs that codify for an orthogonal pair of tRNA.sub.CUA/aminoacil-tRNAsynthetase. This synthetase is able to couple N.sub.epsilon-Acetyl-lysine (“acetyllisine” from now on) to the tRNA.sub.CUA. Also, the yeast must express the LexA-Antigen target construct (without any enzyme fused at the c-term) in which the triplet nucleotides that codifies for the lysine that should be acetylated is replaced with the stop codon “TAG”. LexA-target can be either incorporated by genetic modification of yeast or furnished with the pMICBD plasmids. Simultaneous expression in yeast of these proteins and tRNA results in direct incorporation of acetyllysine in the protein target in lieu of the stop signal derived from TAG (or UAG as for RNA), since Acetyllisine-tRNAcuA is able to recognize UAG codon during translation without interfering with synthesis of the rest of the polypeptide. This method and necessary constructs mentioned are well described in several papers (Neumann et al (2008 and 2009) and Hancock et al. (2010)). Thus, another object of the invention is a method for selecting and determining the ability of an immunoglobulin to bind to a post-translationally modified target in an intracellular environment, which folds and it is post-translationally modified as a native protein intracellularly, comprising the steps of:

[0334] a) providing a nucleic acid encoding an intracellular immunoglobulin which is associated with a first molecule; and

[0335] b) providing a nucleic acid encoding an intracellular target which incorporates a post translational modification (acetylation, phosphorylation, methylation and others) that is genetically encoded via expanded genetic code methods and

[0336] a second molecule,

[0337] wherein said first and second molecules are separable domains of a reporter molecule; and

[0338] c) expressing said first nucleotide sequence together with said second nucleotide sequence in an

[0339] intracellular environment of a cell able to decode such genetically encoded post translational modification,

[0340] wherein binding of said immunoglobulin with said target leads to stable interaction of the first molecule and second molecule, thus producing a detectable reporter molecule that generates a signal, and

[0341] d) detecting said signal from said detectable reporter molecule, wherein said detection of a signal is indicative of stable binding activity between said immunoglobulin and said target in the intracellular environment;

[0342] e) isolating those immunoglobulins that stably bind to the target

[0343] and optionally

[0344] f) selecting those immunoglobulins that do not bind to target that is not post-translationally modified.

[0345] Preferably the insertion of constructs above will disrupt two metabolic genes of L40 yeast not needed for its growth, to not impair its 2-HY system functionality or disrupt no gene at all. As for the protein bait, in case of stable genetic modification in yeast, the construct can be replaced with new baits that need to be acetylated in the same generated strain, for example by including at the ends of the baits specific sites for homologous recombination or site-specific recombination.

[0346] The target PTM could also be genetically encoded, instead than by a reprogrammed stop TAG codon, by a quadruplet codon. Thus, the incorporated tRNA can also be based on a 4-base codon/anticodon strategy instead of the stop three base codon/anticodon method described above (Sisido et al., 2005).

[0347] So-modified yeast strain is then ready for IAC screening with a SPLINT libraries using state-of-the-art protocol.

[0348] In this application, L40 yeast strain has been genetically modified to incorporate the modified tRNAArg-tRNAPyl dimeric tRNA constuct (from Hancock et al., plasmid SMH108 pRS426), and the modified aminoacyl-tRNA synthetase AcKRS3 (from Hancock et al., plasmid pBKkanAcKRS3) that are able to confer to the ribosome the ability to introduce an acetyl-lysine in yeast bait protein in correspondence of the UAG mRNA triplet. Yeast L40 genome has been modified by replacing, by homologous recombination, the ADE2 gene (which is mutated and non functional in this L40 strain) with the above mentioned construct, exploiting auxotrophy of L40 for this metabolite (auxotrophy shows up at the second passage of the culture in a minimal adenine-lacking medium) and the peculiar red phenotype of the ade2 mutant cells. Indeed, the tRNA/aatRNA synthetase construct is inserted in the yeast integrating vector pRSII402, which bears a copy of a functional ADE2 gene. Insertion constructs bear distinct promoter elements (ADH1) and ADH terminators. Kozak sequence is reconstructed for Aminoacyl-tRNA Synthetase coding sequence. As initial proof of principle, the Saccharomyces cerevisiae Histone H3 bait has been created with acetylated lysine number nine. The complete protein sequence of the LexA-AcK9H3 PISA 2.0 bait is reported below.

TABLE-US-00009 >LexA-AcK9H3Histone (PISA 2.0) PROTEIN  (SEQ ID NO: 78) MKALTARQQEVFDLIRDHISQTGMPPTRAEIAQRLGFRSPNAAEEHLKA LARKGVIEIVSGASRGIRLLQEEEEGLPLVGRVAAGEPLLAQQHIEGHY QVDPSLFKPNADFLLRVSGMSMKDIGIMDGDLLAVHKTQDVRNGQVVVA RIDDEVTVKRLKKQGNKVELLPENSEFKPIVVDLRQQSFTIEGLAVGVI RNGDWLEFPGIRRPAANYLFDDEDTPPNPKKEIEFQLTTMFMARTKQTA R(AcK)STGGKAPRKQLASKAARKSAPSTGGVKKPHRYKPGTVALREIR RFQKSTE- >LexA-AcK9H3Histone (PISA 2.0) DNA  (SEQ ID NO: 79) ATGAAAGCGCTGACCGCGCGCCAGCAGGAAGTGTTTGATCTGATTCGCG ATCATATTAGCCAGACCGGCATGCCGCCGACCCGCGCGGAAATTGCGCA GCGCCTGGGCTTTCGCAGCCCGAACGCGGCGGAAGAACATCTGAAAGCG CTGGCGCGCAAAGGCGTGATTGAAATTGTGAGCGGCGCGAGCCGCGGCA TTCGCCTGCTGCAGGAAGAAGAAGAAGGCCTGCCGCTGGTGGGCCGCGT GGCGGCGGGCGAACCGCTGCTGGCGCAGCAGCATATTGAAGGCCATTAT CAGGTGGATCCGAGCCTGTTTAAACCGAACGCGGATTTTCTGCTGCGCG TGAGCGGCATGAGCATGAAAGATATTGGCATTATGGATGGCGATCTGCT GGCGGTGCATAAAACCCAGGATGTGCGCAACGGCCAGGTGGTGGTGGCG CGCATTGATGATGAAGTGACCGTGAAACGCCTGAAAAAACAGGGCAACA AAGTGGAACTGCTGCCGGAAAACAGCGAATTTAAACCGATTGTGGTGGA TCTGCGCCAGCAGAGCTTTACCATTGAAGGCCTGGCGGTGGGCGTGATT CGCAACGGCGATTGGCTGGAATTTCCGGGCATTCGCCGCCCGGCGGCGA ACTATCTGTTTGATGATGAAGATACCCCGCCGAACCCGAAAAAAGAAAT TGAATTTCAGCTGACCACCATGTTTATGGCGCGCACCAAACAGACCGCG CGCGCGTGCTAGAGCACCGGCGGCAAAGCGCCGCGCAAACAGCTGGCGA GCAAAGCGGCGCGCAAAAGCGCGCCGAGCACCGGCGGCGTGAAAAAACC GCATCGCTATAAACCGGGCACCGTGGCGCTGCGCGAAATTCGCCGCTTT CAGAAAAGCACCGAATAA

[0349] Bait sequence is cloned in pMICBD1 plasmid and screening is performed with both mouse or human SPLINT libraries cloned in pLinker220-VP16-AD plasmid or other VP16-AD yeast plasmids.

[0350] Results

[0351] Inventors have shown data to report proof of principle for our invention, the P.I.S.A. technology. In both cases of study (AcH3 Histone and Aclntegrase), inventors have successfully isolated intrabodies targeting the acetylated version of the target, without recognition of the non-acetylated version of the same protein. For both antibodies a proof of principle for their use for a PTM-specific protein silencing in cells has been shown above. Nowadays, it is possible to select antibodies against PTM only from in vitro methods, with previous strong manipulation of the antigen (which is limited to peptide antigens and thus not in a native conformation) and without any warranty of intracellular functionality. For instance, efforts have been made with phage display libraries constructed ad hoc (case by case) studying particular phospho-binding antibody domains (Koeber et al., 2013) or by panning in vitro against PTM-peptides (Hattori et. al., 2013), but these require knowledge of co-crystallization structures and cumbersome protein manipulation respectively. Thus, no general method to select intracellular antibodies against native-folded PTM protein existed previously, paving the way to PISA antibodies as election tools for epigenetic and target validation studies.

[0352] Moreover, the antibody ScFv-58F obtained by the present inventor has proven to be a better binder for the native form of Acetylated Histone H3 with respect to the peptide version of AcK9H3, to bind chromatin in both yeast and mammalian cells, and also to induce a very specific PTM-mediated change in gene expression in a living cellular system (yeast). No other existing intrabody has ever been proven to induce this functional effect.

REFERENCES

[0353] 1) Visintin et al.—“Selection of antibodies for intracellular function using a two-hybrid in vivo system”—PNAS (1999); [0354] 2) Visintin et al.—“The Intracellular Antibody Capture Technology (IACT): Towards a Consensus Sequence for Intracellular Antibodies”—JMB (2002); [0355] 3) Visintin et al.—“The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation”—Methods (2004); [0356] 4) Vascotto et al.—“Design and selection of an intrabody library produced de-novo for the non-structural protein NSP5 of rotavirus”—JIM (2005); [0357] 5) Melchionna and Cattaneo—“A protein silencing switch by ligand-induced proteasome-targeting intrabodies”—JMB (2007); [0358] 6) Zacchi et al.—“Gephyrin selective intrabodies as a new strategy for studying inhibitory receptor clustering”—J Molecular Neuroscience (2008); [0359] 7) Meli et al.—“Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers”—JMB (2009); [0360] 8) Guo et al.—“A tethered catalysis: two-hybrid system to identify protein-protein interactions requiring post-translational modifications”—Nature Biotechnology (2004); [0361] 9) Allouch and Cereseto—“Identification of cellular factors binding to acetylated HIV-1 integrase”—Amino acids (2011); [0362] 10) Sato et al.—“Genetically encoded system to track histone modification in vivo”—Nature scientific Reports (2013); [0363] 11) Koeber et al.—“Nature-inspired design of motif-specific antibody scaffolds”—Nature Biotechnology (2013); [0364] 12) Hattori et al.—“Recombinant antibodies to histone post-translational modifications”—Nature Methods (2013); [0365] 13) Cereseto et al.—“Acetylation of HIV-1 integrase by p300 regulates viral integration.”—Embo Journal (2005); [0366] 14) Siddiqi et al.—“Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas.”—Curr Stem Cell Res Ther (2010); [0367] 15) Beltran et al.—“Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.” Mol Cancer Ther (2008). [0368] 16) Tanaka & Rabbitts—“Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture”—Nature Protocol (2009). [0369] 17) Visintin et al.—“Intracellular antibodies for proteomics”—JIM (2004) [0370] 18) Neumann et al.—“Genetically encoding Nepsilon-acetyllysine in recombinant proteins”—Nat Chem Biol—(2008); [0371] 19) Neumann et al.—“A Method for Genetically Installing Site-Specific Acetylation in Recombinant Histones Defines the Effects of H3 K56 Acetylation”—Molecular Cell (2009); [0372] 20) Hancock et al.—“Expanding the genetic code of yeast for incorporation of diverse unnatural amino acids via a pyrrolysyl-tRNA synthetase/tRNA pair.”—J Am Chem Soc. (2010) [0373] 21) Sisido et al.—“Four-base codon/anticodon strategy and non-enzymatic aminoacylation for protein engineering with non-natural amino acids.”—Methods (2005) [0374] 22) Filippakopoulos et al.—“Selective inhibition of BET bromodomains”—Nature (2010) [0375] 23) Zeng et al.—“Bromodomain: An acetyl-lysine binding domain”—FEBS Letters (2002) [0376] 24) Falkeberg et al.—“Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders”—Nature Reviews Drug Discovery (2014) [0377] 25) Di Martile et al.—“Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells”—Oncotarget (2016) [0378] 26) Zhag et al—“Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action”—The Journak of Investigative Dermatology (2005) [0379] 27) Jenuwein et al.—“Translating the histone code”—Science—(2001) [0380] 28) Wongwisansri et al.—“Disruption of histone deacetylase gene RPD3 accelerates PHOS activation kinetics through inappropriate Pho84p recycling.”—Eukaryotic cell (2005) [0381] 29) Lei et al.—“Tau protein: relevance to Parkinson's disease”—International Journal of Biochemistry & Cell Biology—(2010) [0382] 30) Alonso et al.—“Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments”—PNAS—(2001) [0383] 31) Helma et al.—“Nanobodies and recombinant binders in cell biology”—The journal of cell biology—(2015) [0384] 32) Tanaka et al.—“Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies”—Journal of molecular biology—(2003) [0385] 33) Marks and Bradbury—“PCR cloning of human immunoglobulin genes”—Methods in Molecular Biology—(2004) [0386] 34) Lang and Chin—“Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins”—Chemical reviews—(2014) [0387] 35) Marshall—“Gene Therapy on trial”—Science—(2000) [0388] 36) Cerrato et al—“Cell-penetrating peptides with intracellular organelle targeting”—Expert Opin Drug Deliv13 (2016)